In a phase I study, Liu et al. evaluated compound CAR-T cells targeting both CD33 and CLL-1 in R/R AML; 2 patients who had blast counts >20% before cCAR T cell infusion achieved MRD-negative remission and were able to proceed to allo-HSCT (165). Here, CD33 is linked to acute myeloid leukemia.